Biotech · Private company
AVEO Pharmaceuticals, Inc.
Track this companyFree. Adds AVEO Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials153 recruiting or active
Pipeline programs24From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline24
- CetuximabPhase 3 · Metastatic Head-and-neck Squamous-cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- FiclatuzumabPhase 3 · Metastatic Head-and-neck Squamous-cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 3 · Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- SorafenibPhase 3 · Carcinoma, Renal CellClinicalTrials.gov · fetched Nov 12, 2026
- SorafenibPhase 3 · Advanced Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- TivozanibPhase 3 · Advanced Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- TivozanibPhase 3 · Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- tivozanib (AV-951)Phase 3 · Advanced Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Tivozanib hydrochloridePhase 3 · Carcinoma, Renal CellClinicalTrials.gov · fetched Nov 12, 2026
- DurvalumabPhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- ErlotinibPhase 2 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- FiclatuzumabPhase 2 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- paclitaxelPhase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- SunitinibPhase 2 · Metastatic Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- TivozanibPhase 2 · Metastatic Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- TivozanibPhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Tivozanib HydrochloridePhase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- AV-380Phase 1 · CachexiaClinicalTrials.gov · fetched Nov 12, 2026
- TivoSolid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- TivozanibSolid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Tivozanib (AV-951)Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Tivozanib + capecitabineSolid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Tivozanib + paclitaxelSolid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Tivozanib + temsirolimusSolid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials15
- A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell CarcinomaPHASE3 · RECRUITING · started Jan 11, 2024ClinicalTrials.gov NCT06064877 · fetched Nov 12, 2026
- Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell CarcinomaPHASE2 · RECRUITING · started Jan 5, 2024ClinicalTrials.gov NCT06053658 · fetched Nov 12, 2026
- A Dose Escalation Study of AV-380 in Cancer Patients With CachexiaPHASE1 · COMPLETED · started Jun 13, 2023ClinicalTrials.gov NCT05865535 · fetched Nov 12, 2026
- Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell CarcinomaPHASE3 · COMPLETED · started Sep 9, 2021ClinicalTrials.gov NCT04987203 · fetched Nov 12, 2026
- A Phase 1 Study of AV-380 in Healthy SubjectsPHASE1 · COMPLETED · started Feb 22, 2021ClinicalTrials.gov NCT04815551 · fetched Nov 12, 2026
- A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular CarcinomaPHASE1_PHASE2 · TERMINATED · started Sep 30, 2019ClinicalTrials.gov NCT03970616 · fetched Nov 12, 2026
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPHASE2_PHASE3 · RECRUITING · started Nov 1, 2016ClinicalTrials.gov NCT03013998 · fetched Nov 12, 2026
- A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)PHASE3 · COMPLETED · started May 24, 2016ClinicalTrials.gov NCT02627963 · fetched Nov 12, 2026
- A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive LabelPHASE2 · TERMINATED · started Nov 1, 2014ClinicalTrials.gov NCT02318368 · fetched Nov 12, 2026
- Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast CancerPHASE2 · TERMINATED · started Nov 1, 2012ClinicalTrials.gov NCT01745367 · fetched Nov 12, 2026
- A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCCPHASE2 · TERMINATED · started Jul 1, 2012ClinicalTrials.gov NCT01673386 · fetched Nov 12, 2026
- A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell CarcinomaPHASE2 · COMPLETED · started Jan 1, 2011ClinicalTrials.gov NCT01297244 · fetched Nov 12, 2026
- A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib ProtocolsNA · TERMINATED · started Jun 1, 2010ClinicalTrials.gov NCT01369433 · fetched Nov 12, 2026
- An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).PHASE3 · COMPLETED · started Mar 1, 2010ClinicalTrials.gov NCT01076010 · fetched Nov 12, 2026
- A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell CarcinomaPHASE3 · COMPLETED · started Dec 1, 2009ClinicalTrials.gov NCT01030783 · fetched Nov 12, 2026